VBI Vaccines Announces Third Positive DSMB Review In Phase 1/2a Study Of VBI-1901 In Recurrent GBM Patients; Independent Data And Safety Monitoring Committee Unanimously Recommends Continuation Of Study Without Modification
Benzinga Newsdesk